PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 65.39

Change

-1.82 (-2.71)%

Market Cap

USD 3.76B

Volume

0.86M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-20 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.56 (-0.63%)

USD 33.92B
PODD Insulet Corporation

-5.49 (-1.90%)

USD 19.53B
MASI Masimo Corporation

-7.25 (-4.09%)

USD 9.33B
BRKR Bruker Corporation

-2.10 (-3.97%)

USD 8.82B
NARI Inari Medical Inc

N/A

USD 4.67B
IRTC iRhythm Technologies Inc

+6.77 (+6.01%)

USD 3.53B
QDEL Quidel Corporation

-0.57 (-1.39%)

USD 2.76B
LIVN LivaNova PLC

-0.55 (-1.15%)

USD 2.71B
NVCR Novocure Ltd

+0.44 (+2.03%)

USD 2.65B
TMDX TransMedics Group Inc

-3.50 (-4.64%)

USD 2.44B

ETFs Containing PRCT

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.79% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.79% 25% F 16% F
Trailing 12 Months  
Capital Gain 33.01% 81% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.01% 81% B- 78% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.56% 72% C 82% B
Dividend Return 32.56% 72% C 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.96% 57% F 35% F
Risk Adjusted Return 59.24% 96% N/A 82% B
Market Capitalization 3.76B 95% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.